OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Our expert, award-winning staff selects the products we cover and rigorously researches and tests our top picks. If you buy through our links, we may get a commission. Executive Editor David ...